Design issues in dose-finding phase i trials for combinations of two agents

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 509-523

  Fan, Shenghua Kelly ^a   Venook, Alan P ^b   Lu, Ying ^c  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dose escalation; Dose limiting toxicity (DLT); Isotonic estimation; Maximum tolerated dose (MTD); Phase I trial

Indexed keywords

ALGORITHM; ARTICLE; CANCER THERAPY; CLINICAL STUDY; DOSE CALCULATION; DOSE LIMITING TOXICITY; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION; TOXICITY; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; NEOPLASM; PHASE 1 CLINICAL TRIAL; STATISTICS; THEORETICAL MODEL;

ANTINEOPLASTIC AGENT;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, THEORETICAL; NEOPLASMS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 67651017803     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902802433     Document Type: Article

References (12)

1. Al-Batran, S., Atmaca, A., Schleyer, E., Pauligk, C., Hosius, C., Ehninger, G., Jager, E. (2007). Imatinib mesylate for targeting the platelet-derived growth factor - receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer-A dose-escalation Phase I trial. Cancer 109(9):1897-1904.
2. Bourgeois, H., Joly, F., Pujade-Lauraine, E., Cure, H., Guastalla, J. P., Ferru, A., Chabrun, V., Chieze, S., Tourani. J. M. (2006). Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients. Am. J. Clin. Oncol. 29(4):399-404.
3. Chevret, S. (2006). Basic concepts in dose-finding. In: Chevret, S., ed. Statistical Methods for Dose-Finding Experiments. West Sussex, England: John Wiley & Sons Ltd., pp. 5-18.
4. Conaway, M., Dunbar, S., Peddada, S. (2004). Designs for single- or multiple-agent Phase I trials. Biometrics 60(3):661-669.
5. Gelmon, K., Stewart, D., Chi, K. N., Chia, S., Cripps, C., Huan, S., Janke, S., Ayers, D., Fry, D., Shabbits, J. A., Walsh, W., McIntosh, L., Seymour, L. K. (2004). A Phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: A National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Ann. Oncol. 15(7):1115-1122.
6. Koyfman, S. A., Agrawal, M., Garrett-Mayer, E., Krohmal, B., Wolf, E., Emanuel, E. J., Gross, C. P. (2007). Risks and benefits associated with novel Phase 1 oncology trial designs. Cancer 110(5):1115-1124.
7. Leung, D. H., Wang, Y.-G. (2001). Isotonic designs for Phase I Trials. Contr. Clin. Trials 22:126-138.
8. Machida, S., Ohwada, M., Fujiwara, H., Konno, R., Takano, M., Kita, T., Kikuchi, Y., Komiyama, S., Mikami, M., Suzuki, M. (2003). Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncol. 65(2):102-107.
9. Mandrekar, S., Cui, Y., Sargent, D. (2007). An adaptive Phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat. Med. 26(11):2317-2330.
10. Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, R., Ludwig, M., Flashar, C., Voigtmann, R., Scheulen, M. E., Seeber, S., Strumberg, D. (2006). Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann. Oncol. 17:866-873.
11. Shih, W., Lin, Y. (2006). Traditional and modified algorithm-based designs for Phase I cancer clinical trials. In: Chevret, S., ed. Statistical Methods for Dose-Finding Experiments. West Sussex, England: John Wiley & Sons Ltd., pp. 61-90.
12. Vincent, P. Z., Hang, X., Chen, C. (2003). Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, venorelbine, gemcitabine or doxorubicin. Proc. Am. Assoc. Cancer Res. 44(2nd edn):Abstr. 719.